Abiopharma

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

Yes! These Numbers Still Hurt My Feelings! | NRC Health Webcast

Change in the Company’s holdings in Citycon, holds approximately 89.8%

Investor Presentation - Q2 2026

Notice of annual meeting for 6.10.26 – reappointments, proxy card and more

Dividend in the amount of 119.216 agorot per share, record date 2.9.26, payment 10.9.26

Events and transactions

Transaction with a controlling shareholder – engagement in an insurance policy for officers

The company’s liability position as of 30.6.26, by repayment dates

Financial Statements Q2 2026 Investor Presentation

Q2/half-year report for 2026

The company’s liability position as of 30.6.26, by repayment dates

Q2/half-year report for 2026

The company’s outstanding liabilities as of June 30, 2026, by maturity dates